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Abstract
Rationale: Sepsis is a common cause of death in the intensive care unit with mortality up to 70% when accompanied by
multiple organ dysfunction. Rapid diagnosis and the institution of appropriate antibiotic therapy and pressor support are
therefore critical for survival. MicroRNAs are small non-coding RNAs that play an important role in the regulation of
numerous cellular processes, including inflammation and immunity.
Objectives: We hypothesized changes in expression of microRNAs during sepsis may be of diagnostic value in the intensive
care unit (ICU).
Methods: Massively parallel sequencing of microRNAs was utilised for screening microRNA candidates. Putative microRNAs
were validated using quantitative real-time PCR (qRT-PCR). This study includes data from both a training cohort (UK) and an
independent validation cohort (Sweden). A linear discriminant statistical model was employed to construct a diagnostic
microRNA signature.
Results: A panel of known and novel microRNAs were detectable in the blood of patients with sepsis. After qRT-PCR
validation, microRNA miR-150 and miR-4772-5p-iso were able to discriminate between patients who have systemic
inflammatory response syndrome and patients with sepsis. This finding was also validated in independent cohort with an
average diagnostic accuracy of 86%. Fractionating the cellular components of blood reveals miR-4772-5p-iso is expressed
differentially in monocytes. Functional experiments using primary human monocytes demonstrate that it expressed in
response to TLR ligation.
Conclusions: Taken together, these data provide a novel microRNA signature of sepsis that should allow rapid point-of-care
diagnostic assessment of patients on ICU and also provide greater insight into the pathobiology of this severe disease.
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Introduction
Sepsis and its sequelae constitute a major health problem in the
developed world in terms of morbidity, mortality and cost. An
ageing population, higher frequencies of invasive procedures,
greater prevalence of multi-drug resistant organisms in hospitals
and iatrogenic immunosuppression have led to an expanding
population of susceptible individuals. The overall cost of treatment
exceeds $3.5 billion per year in the UK and $16.7 billion per year
per year in the US [1]. From the perspective of individualized
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treatment strategies, difficulties in diagnosing sepsis rapidly and
accurately have helped contribute to delays in the administration
of adequate antibiotic treatment and ICU services. The absence of
a validated diagnostic test leads to the empirical use of broad-
spectrum antibiotics and the inappropriate deployment of
expensive, potentially life-saving technology, without significant
improvements in clinical outcomes for affected patients [2,3].
While tests like C-reactive protein (CRP), procalcitonin, and
neutrophil CD64 expression have some value, none possess the
essential characteristics required to have a significant impact on
morbidity, mortality and cost.
In the US and the EU combined, approximately 1.5 million
hospitalized patients are diagnosed with sepsis per year. In the
ICU, the most expensive form of care given to hospitalized
Table 1. Diagnostic criteria for sepsis [18].
Infection, documented or suspected, and some of the following:
General variables
Fever (core temperature .38.3uC)
Hypothermia (core temperature ,36uC)
Heart rate .90 min21 or .2 SD above the normal value for age
Tachypnea
Altered mental status Significant edema or positive fluid balance (.20 mL/kg over 24 hrs)
Hyperglycemia (plasma glucose .120 mg/dL or .7.7 mmol/L) in the absence of diabetes
Inflammatory variables Leukocytosis (WBC count .12,000 mL21)
Leukopenia (WBC count ,4000 mL21)
Normal WBC count with .10% immature forms
Plasma C-reactive protein .2 SD above the normal value
Plasma procalcitonin .2 SD above the normal value
Hemodynamic variables
Arterial hypotension (SBP,90 mm Hg, MAP,70, or an SBP decrease .40 mm Hg in adults or ,2 SD below normal for age)
SvO2 ,70%b; Cardiac index ,3.5 L?min21?M223
Organ dysfunction variables
Arterial hypoxemia (PaO2/FIO2 ,300)
Acute oliguria (urine output ,0.5 mL?kg21? hr21 or 45 mmol/L for at least 2 hrs); Creatinine increase .0.5 mg/dL
Coagulation abnormalities (INR.1.5 or aPTT.60 secs)
Ileus (absent bowel sounds)
Thrombocytopenia (platelet count ,100,000 mL21)
Hyperbilirubinemia (plasma total bilirubin .4 mg/dL or 70 mmol/L)
Tissue perfusion variables
Hyperlactatemia (.1 mmol/L)
Decreased capillary refill or mottling
doi:10.1371/journal.pone.0075918.t001
Table 2. Demographic and clinical information (UK cohort).
Healthy subjects
(n =21) Patients with SIRS (n=22) Patients with Sepsis (n=23)
p-value between
patients group
Age 42 (27–61) 57(27–92) 61 (35–87) 0.4008
Male 7 (33.3%) 16 (72.7%) 8 (34.9%) 0.0108
APACHEII score — 12 (4–20) 18 (9–27) 0.016
SOFA score — 3 (1–8) 6 (1–14) 0.0319
1-month mortality rate — 7 (31.8%) 0 —
CRP — 53 (5–123) 242 (45–489) p,0.0001
WBC count — 14.8 (12.1–47.0) 16.8 (13.3–28.7) 0.0266
Neutrophils count — 12.55 (6.6–30.1) 14.55 (8.6–26.9) 0.0573
Temperature — 36.8 (34.5–37.9) 36.15 (34.4–38.1) 0.1889
Data are presented as numbers (percentages) for categorical variables and as median values (ranges) for continuous variables. Statistics: The distribution of sex was
tested using Pearson Chi-Square Tests, the rest variables were tested using Mann-Whitney U test.
doi:10.1371/journal.pone.0075918.t002
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patients, approximately 15% of patients develop severe sepsis and
septic shock [1,4]. Overall mortality exceeds 40%, and this
represents close to 30% of all hospital-based deaths [5]. These data
show that there is an unmet healthcare need for a biomarker that
could decrease overall mortality, morbidity and healthcare-
associated costs as a result of more rapid and accurate diagnosis.
MicroRNAs are a class of RNA molecules that control post-
transcriptional gene expression primarily by complementary base
pairing with specific ‘‘seed’’ sequences in the 39UTR of their target
mRNAs [6,7]. The expression levels of specific microRNAs can be
of diagnostic value in various forms of malignancy [8,9,10] and
may also provide insight into disease pathogenesis [9,11].
Recently, a number of studies have looked at a limited set of
microRNAs and have shown that their expression is altered in the
context of inflammation or sepsis, both in vitro [12,13] and in vivo
[10,14].
Given that the total number of microRNAs in the human
genome is incompletely defined and that pre-clinical models of
sepsis are not as informative as in other diseases [15,16,17], we
took the approach of massive parallel sequencing of all micro-
RNAs (mir-seq) present in the circulating blood leucocytes in
patients with SIRS, sepsis and healthy controls. Novel microRNA
signatures that discriminated between these three clinically-
assigned diagnostic categories were then validated by real-time
PCR analyses in an observational clinical study. This signature
was then cross-validated using samples from an independent
cohort. Mechanistic pathways were tested by fractionation of the
circulating blood populations and dissection of candidate upstream
pathways capable of inducing the expression of these candidate
microRNAs in vitro in primary human cells.
Methods
Ethics Statement
On behalf of all authors, I certify that this study involving
human subjects is in accordance with the Helsinki declaration of
1975 as revised in 2008. Study in UK was approved by St
Thomas’ Hospital Research Ethics Committee/South East
London REC 2; and study in Sweden cohort was approved by
the regional ethical review board in Uppsala, Sweden. All patients
were written informed consent.
Table 3. Clinical diagnosis and microbiological information.
Cohort Group Clinical Diagnosis Microbiological culture results
UK SIRS Coronary Artery Bypass Grafts (n = 9); Aortic dissection (n = 2); Aortic Valve
Replacement (n = 1); Trans Apical Aortic Valve Replacement (n = 1);
Burn (n = 1); Abdominal Aortic Aneurysm (n = 1); Post operative trauma
(n = 4); Others (n = 3)
No relevant positive culture results
Sepsis Intra-abdominal Sepsis (n = 5); Pneumonia (n = 4); Lower respiratory tract
infection (n = 3); Bloodstream infection (n = 3); Biliary Sepsis (n = 2); Others
(n = 6)
G-ve. Sepsis (n=7), with 2 blood
stream infection: P.aeruginosa, E. cloacae,
E.Coli, Klebsiella spp, H. influenzae, C. koseri;
G+ve. Sepsis (n = 3): Streptococcus spp,
Enterococcus spp, S. Aureus; Mixed G+ve. &
G-ve. Blood stream infection (n = 1): S.
aureus; P. aeruginosa
Sweden None Sepsis All patients were at admission subjected to blood culture, but discharged
without evidence of bacterial infection. Mostly viral infections (e.g. influenza,
gastro-enteritis) or inflammatory reactions (e.g. reactive arthritis,
pseudo-gout)
No relevant positive culture results
Sepsis Lower respiratory tract infection/Pneumonia (n = 8); Urinary Tract
Infection/Pyelo-nephritis (n = 5;) Endocarditis (n = 2); Biliary Sepsis (n = 1);
Septic Arthritis (n = 1); Tissue Disease/Abscesses (n = 2); Others (n = 3)
Blood Stream Infection/Positive blood
culture (n =17): S.aureus (n = 4); E.coli
(n = 4); S. pneumoniae (n = 2); Streptococcus
spp (n = 4) E.faecalis (n = 1); S. marcescens
(n = 1); P. aeruginosa (n = 1)
doi:10.1371/journal.pone.0075918.t003
Table 4. Demographic and clinical information (Swedish Cohort).
Patients with no evidence of sepsis
(n=15)
Patients with severe sepsis/
septic shock (n=23) p-value
Age 69 (23–75) 68 (33–78) 0.89
Male 8 (53.3%) 15 (65.2%) 0.46
Septic shock 0 5 (21.7) —
ICU admission 0 10 (43.5%) —
1-month mortality rate 0 5 (21.7%) —
CRP 44(1.3-202) 167 (17-488) 0.001
Data are presented as numbers (percentages) for categorical variables and as median values (ranges) for continuous variables. Statistics: The distribution of sex was
tested using Pearson Chi-Square Tests, the rest variables were tested using Mann-Whitney U test.
doi:10.1371/journal.pone.0075918.t004
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Patients and study design
A clinical study was carried out in the Intensive Care Unit (ICU)
at Guy’s and St.Thomas’ Hospital, London (Ethic approval REC
reference No. 08/H0802/110) as training cohort. Eligible patients
or healthy volunteers signed informed consent where possible, for
patients who were unconscious a signed informed consent was
taken by their legal representatives as approved by local ethic
committee. For each individual, 20 ml of blood was taken by
venepuncture and blood from ICU patients was obtained from
existing central venous catheters using EDTA anti-coagulated
Vacutainers (BD Biosciences, NJ, USA). Whole blood was stored
at 4uC before transfer to the research lab for processing. All studies
were carried out in a double-blind fashion with research nurses
taking samples and collecting clinical information; laboratory
results were generated without knowing the nature of samples.
ICU physicians and microbiologists then reviewed the clinical and
lab data and grouped the patients according to validated clinical
definitions [18] (Table 1). Inclusion and Exclusion Criteria are
listed in supplementary data (See Supporting Information S1 in
File S1). A total of 23 sepsis patients and 22 SIRS patients were
included in this study, together with 21 healthy volunteers.
For the validation cohort in Sweden, the study was carried out
at The Department of Infectious Diseases, O¨rebro University
Hospital, Sweden (approved by local ethics committee). A total of
1093 patients were recruited from this cohort as previously
described [19] and all patients signed informed consent. A positive
blood culture was found in 138 patients. A retrospective chart
review was performed by a specialist of infectious diseases. 17
patients with positive blood culture and were diagnosed with
severe sepsis or septic shock. Another 6 patients had blood culture
negative however were diagnosed with clinical infection and severe
sepsis or septic shock. Together those 23 patients form the severe
sepsis-group of O¨rebro. 15 patients had negative blood cultures
and negative SeptiFast PCR results form the non-infected group of
O¨rebro.
Small RNA library and HiSeq Sequencing
RNA extraction was performed as described using a standard
TRIzol LS protocol [20]. Small RNA fraction purification and
sequencing (FASTERIS SA, Switzerland) were performed as
previously described [21] and miRbase version 16 was used in this
study. cDNA were purified on a gel and the library was quantified
before dilution to 10 nM. The diluted cDNA library was then
sequenced with a spike PhiX reference on a HiSeq (Illumina)
according to the manufacturer’s instructions. After adapter
removal, reads were mapped to the human genome (NCBI build
37) and only reads having at least 17 nucleotides with an identity
of 100% on the human genome are conserved. Reads mapped to
miRNAs were counted and normalized by the total number of
reads mapping the human genome per million (RPM).
Quantitative reverse transcription polymerase chain
reaction (qRT-PCR) for miRNA Expression
MiRNA levels were detected by qRT-PCR using the Exiqon
custom LNATM primers (Exiqon, Vedbaek, Denmark) according
to the manufacturer’s instructions. Given the lack of consensus
about the validity and accuracy of normalization for microRNAs
in biomarker studies, raw Ct values were used [22]. The fold
change of each miRNA was calculated from the equation 22DCT,
where DCT=Mean CtmiRNA-A2Mean CtmiRNA-B (where Ct is the
threshold cycle for a sample). The relative abundance of each
miRNA was calculated as the ratio of the value from sepsis to the
value from controls (stimulated monocytes to non-stimulated
monocytes in in vitro experiments), producing a fold change value.
Peripheral monocyte purification and in vitro stimulation
PBMCs were purified using Ficoll-Hypaque separation method
as previously described [23]. Monocytes were positively selected
using magnetic beads conjugated to an anti-CD14 antibody
(Miltenyi, Germany). Monocytes isolated from healthy donors
Figure 1. Fold Changes of microRNA sequencing data and candidate microRNA expression validated by qRT-PCR. (A) Each bar
represents fold increase or decrease in the number of reads for one microRNA candidate comparing sepsis group with SIRS group; grey bar
represents fold change data from septic patients with low CD64 expression whereas black bar represents patients with high CD64 expression. A pool
of 4 whole blood samples for each group was used for sequencing experiments; (B) Box and whisker plot shows microRNA expression in raw Ct
values (Y axis) of 7 candidate microRNAs (X axis); n = 61; (C) to (I) microRNA levels of 7 candidates and (J) mRNA level of IL-18RAP (normalized to
GUSB) in samples from healthy donors (n = 17), sepsis patients (n = 22) and SIRS patients (n = 22) detected by qRT-PCR. Kruskal-Wallis ANOVA test was
applied, * significant at p,0.05, ** significant at p,0.01, *** significant at p,0.001.
doi:10.1371/journal.pone.0075918.g001
Table 5. Demographic and clinical information for patients used for sequencing.
Sepsis patients CD64 high,
(n =4)
Sepsis patients CD64 low,
(n =4) SIRS patients (n =4) p-value
Age 65 (61–74) 73 (52–87) 70 (43–84) 0.4724
Male 3 (75%) 1 (25%) 2 (50%) 0.3679
Clinical Diagnosis Intra-abdominal Sepsis (n = 2;
Acute Kidney Infection in both
cases); Pneumonia (n = 1);
Biliary Sepsis (n = 1)
Pneumonia (n = 2); Lower
respiratory tract infection
(n = 2)
Coronary Artery Bypass Grafts (n = 1) Aortic
Valve Replacement (n = 1); Trans Apical
Aortic Valve Replacement (n = 1); Post
operative trauma (n = 1, tracheal dilatation)
n/a
CRP 328 (203–498) 153 (45–305) 68 (25–100) 0.0559
WBC count 20.7 (15.5–23.7) 15.9 (13.3–18.8) 15.2 (12.5–19.5) 0.0775
Neutrophils count 19.3 (13.5–22.8) 14.0 (11.2–17.3) 12.7 (9.9–17) 0.0684
Temperature 36.0 (35.2–36.7) 36.3 (34.4–37.7) 36.7 (36.5–37.0) 0.3829
Data are presented as numbers (percentages) for categorical variables and as median values (ranges) for continuous variables. Statistics: The distribution of sex was
tested using Pearson Chi-Square Tests, the rest variables were tested using Kruskal-Wallis ANOVA test.
doi:10.1371/journal.pone.0075918.t005
A Validated microRNA Signature for Sepsis
PLOS ONE | www.plosone.org 5 October 2013 | Volume 8 | Issue 10 | e75918
were subsequently cultured with RPMI-1640 supplemented with
10% FCS at concentration of 16106/ml in a 6-well culture dish in
5 ml/well. TLR ligands were added into culture for for 24 hrs in
37uC, with 5% CO2 at the concentrations suggested by Taganov et
al [24]: 10 mg/ml peptidoglycan (PGN), 100 ng/ml Pam3CSK4,
25 mg/ml poly(I:C), 100 ng/ml LPS (E. coli 055:B5), 10 mg/ml
ultrapure LPS (E. coli strain K12), 100 ng/ml recombinant
flagellin (S. typhimurium), 5 mg/ml imiquimod-R837 and 5 mM
CpG oligonucleotide type C (all TLR ligands were purchased from
InvivoGen, USA). RNA was harvested at the end of culture using
Trizol RNA isolation method for qRT-PCR. In some experi-
ments, patient samples were isolated for both CD14+ monocytes
and CD14+ depleted PBMCs using same method, in order to have
total RNA for sequencing.
Statistical Analysis
For sequencing data, raw reads obtained from each library were
normalized to RPM. For qRT-PCR, the primary analysis was the
comparison between Sepsis and non-sepsis groups (SIRS and
healthy subjects). Variables for sepsis prediction were assessed
using univariate analysis on the first cohort, and those that were
statistically significant (p,0.05) in this analysis were included in
multivariate analysis by adopting a multiple stepwise linear
discriminant analysis (LDA) model based on a p value of ,0.05.
The second cohort was then used to validate this LDA model.
Microsoft Excel 2007, SPSS 17.0 and Graphpad Prism 4.0 were
chosen for constructing graphs and statistical analysis. Specific
statistical test methods are indicated in the figure legends.
Table 6. Sequencing information of a selection of candidate microRNAs*.
No MicroRNA Candidates Information Reads per Million (RPM)
Mirbase name Sequence
Length
(nt) HEALTHY(n=4) SIRS (n =4) Sepsis
High CD64
(n =4)
Low CD64
(n=4)
1 miR-342-3p TCTCACACAGAAATCGCACCCGT 23 1135.61 91.36 49.96 65.19
2 mir-3173-3p TGCCCTGCCTGTTTTCTCCTTT 22 19.34 0.48 0.62 0.37
3 miR-191-iso CAACGGAATCCCAAAAGCAGCT 23 24388.49 2594.81 2010.12 2549.78
4 miR-4772-3p CCTGCAACTTTGCCTGATCAGA 22 6.02 2.89 11.11 3.99
5 miR-4772-5p-iso TCTGATCAGGCAAAATTGCAGA 22 0.51 1.21 11.39 3.49
6 miR-4772-5p TGATCAGGCAAAATTGCAGACT 22 0.13 0.65 4.83 0.85
7 miR-150 TCTCCCAACCCTTGTACCAGTG 22 649.83 151.43 56.08 69.54
8 miR-146a TGAGAACTGAATTCCATGGGTT 22 273.42 526.72 383.41 485.05
9 miR-146b-5p TGAGAACTGAATTCCATAGGCT 22 235.67 366.9 296.69 389.04
10 miR-223 TGTCAGTTTGTCAAATACCCCA 22 37072.6 9987.9 16585.9 10708.9
11 miR-125b TCCCTGAGACCCTAACTTGTGA 22 399.6 28.97 41.77 24.57
12 miR-125a-5p TCCCTGAGACCCTTTAACCTGTGA 24 138.77 18.06 15.59 17.92
*Over 400 microRNA were identified in whole blood samples but only ones that of potential diagnostic interest or previously reported related with infection and sepsis
were listed;
doi:10.1371/journal.pone.0075918.t006
Figure 2. Simplified diagram illustrates the genomic location of miR-4772 family on Chromosome q12.1 within intron 5 of IL-18
RAP.
doi:10.1371/journal.pone.0075918.g002
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Results
Study overview of training and validation cohorts
22 SIRS patients, 23 septic patients and 21 healthy donors were
recruited from ICU at Guy’s and St.Thomas’ Hospital, UK.Within
the sepsis group, 7 had Gram negative sepsis (2 bacteremia), 3 had
Gram positive sepsis, 1 had a mixture of both and the remaining 11
cases were diagnosed clinically according to validated clinical
diagnostic criteria in a blinded manner (Table 2 and Table 3).
23 septic patients and 15 none septic patients recruited in O¨rebro
University Hospital, Sweden were used as an independent validation
cohort. Within the sepsis group, 17 had positive blood cultures and the
remaining 6 cases were diagnosed clinically. 10 septic patients (43%)
were admitted into ICU after blood samples were taken. Clinical
diagnoses for both patient groups are listed in Table 3 and Table 4.
Septic patients from both cohorts had significantly higher CRP
measurements than the SIRS or non-infected group, but no
difference in body temperature or neutrophil count was observed
in both cohorts despite an elevated white cell count of septic
patients in UK cohort (Table 2 and Table 4).
Identification of microRNA candidates
Pooled RNAs of 4 samples in each groups of healthy volunteers,
SIRS or sepsis patients were used for small RNA sequencing.
FACS phenotyping showed that neutrophil CD64 expression
correlated with sepsis (Figure S1 in File S1). Therefore, sequencing
data was grouped as CD64high or CD64low sepsis vs. SIRS
(Figure 1 A). Patients were age and sex matched among different
groups (Table 5). Out of more than 400 detected miRNA
sequences, only those with a fold change 62 and a number of
reads .20 were selected for further analysis (Table 6). The quality
of sequencing was validated for a further 3 samples using RNA
derived from whole blood, monocyte depleted PBMCs and
CD14+ monocytes. 15 to 62 million total reads were achieved
with an overall quality of read above 90% (Table S1 in File S1).
A group of microRNAs related to miR-4772 demonstrated
potential in differentiating sepsis from SIRS, namely miR-4772-
3p, miR-4772-5p and miR-4772-5p-iso (an isomir of miR-4772-
5p). miR-4772 was the first identified microRNA family
upregulated during sepsis, with a distinctive fold change compared
with the SIRS group, especially in CD64 high samples (Figure 2
A). MiR-4772-5p-iso drew our particular interest for two reasons;
firstly it was more abundantly expressed than mir-4772-5p, the
isoform reported first and registered on mirbase; secondly it
yielded the largest sepsis/SIRS fold increase among the 3 (average
of 6 fold). Hs-mir-4772 is located in intron 5 of Interleukin 18
receptor accessory protein (IL-18RAP, Figure 2). Given that
microRNAs embedded within protein coding genes are often co-
regulated, we also assessed IL-18RAP mRNA expression as a
potential biomarker of sepsis. miR-150 was chosen as a potential
candidate because it decreased markedly during inflammation as
previously reported [10] and also show considerable differences in
expression between SIRS and Sepsis (Figure 1 A).
We also identified 3 microRNAs, miR-342, miR-3173-5p and
miR-191, which were profoundly decreased (.10 fold) during
SIRS and sepsis compared with healthy subjects (Table 6). Their
dynamics during inflammation has not previously been reported in
the literature. Although the fold differences between SIRS and
sepsis for these 3 candidates were overall less than to miR-4772
family (Figure 1 A), they were analyzed further because of their
potential biological relevance in systemic inflammation.
Candidates showing discriminative potential for sepsis were
chosen and validated by qRT-PCR with RNA from 61 whole
blood samples (healthy n= 17, sepsis n = 22, SIRS n= 22) (Figure 1
B). Twelve different microRNAs were tested by qRT-PCR in all
patient samples. Seven of these were retained because they
correlated well with the sequencing data and showed a significant
p value (p,0.05) by ANOVA (Table 6, Figure 1). The expression
pattern confirmed the sequencing data. Interestingly, miR-4772-
5p-iso was expressed at a higher level than miR-4772-5p, but not
as highly expressed as miR-4772-3p (Figure 1 B).
Analysis of the qRT-PCR results then focused on whether
candidates had differential expression in the sepsis patient group
compared with both the SIRS group and healthy controls. All 7
microRNA candidates had highly significantly different expression
between septic patients and healthy donors (p,0.001) (Figure 1 C–
J). First of all, analysis was focused on which candidates distinguish
sepsis from both SIRS and healthy subjects. miR-342-3p, miR-
3173-5p and miR-4772-5p-iso had significantly increased expres-
sion in septic patients compared with the other two groups. The
mRNA level of IL18RAP (the gene which hosts miR-4772-5p)
normalized by b Glucuronidase, GUSB was also increased in
septic patients compared with both SIRS and healthy controls
(Figure 1 H). miR-4772-5p-iso was the most significantly up-
regulated microRNA in the septic group (p,0.001). Furthermore,
miR-150 not only distinguished sepsis from SIRS and healthy
subjects, but also showed an elevated level in SIRS compared with
healthy subjects (Figure 1 F). On the other hand, miR-4772-3p
and miR-4772-5p were increased both in sepsis and SIRS
condition compared with healthy subjects (Figure 1 G&I), which
might be more related with inflammation rather than infection.
A direct correlation between IL18 levels and miR-150
Table 7. Multivariate ANOVA analysis of UK cohort (Sepsis vs. SIRS).
Gene Df Sum Sq Mean Sq F value Pr(.F) Significance
miR-150 1 2.533136771 2.533136771 15.70689721 0.000404617 ***
miR-4772-5p-iso 1 2.068628272 2.068628272 12.82667877 0.001151121 **
miR-191 1 0.424406741 0.424406741 2.631564603 0.114886364
miR-342-3p 1 0.063767783 0.063767783 0.395396737 0.534082531
miR-4772-3p 1 0.048997072 0.048997072 0.303809879 0.585454953
miR-3173-5p 1 0.001356836 0.001356836 0.008413161 0.927508062
IL18RAP (noramlized to GUSB) 1 0.000382344 0.000382344 0.002370752 0.961478409
*significant at p,0.05,
**significant at p,0.01,
***significant at p,0.001.
doi:10.1371/journal.pone.0075918.t007
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down-expression has previously been shown (G.calin). As IL18 and
IL18RAP are closely located, we hypothetize that IL18RAP and
its’ intronic microRNA miR-4772-5p are co-ordinately regulated.
LDA modeling generates a novel microRNA score that
distinguishes septic patients from SIRS
Further analysis employed a multivariate ANOVA test to select
the best microRNA candidates in order to construct a scoring
system in distinguishing sepsis from SIRS. Based on a multivariate
test ranking, miR-150 and miR-4772-5p-iso were the top two
candidates and therefore chosen for a Linear Discriminant
Analysis (LDA) to generate a ‘‘sepsis score’’ (Table 7).
The LDA score discriminated sepsis from both SIRS and
healthy groups at a highly significant level in the training cohort
(Figure 3 A). When a cut-off value of 20.2 was chosen, sepsis was
successfully diagnosed in 90.9% of patients (20/22, Figure 3 B).
LDA achieved an AUC of 0.90, with better specificity (90.5%) and
sensitivity (81.8%) than miR-150 or miR-4772-5p-iso alone, which
only gave specificities and sentisitivities of 85.7% and 72.7%, or
71.4% and 68.2% respectively (Figure 3 C–E).
Validation of the LDA score in a second independent
cohort
qRT-PCR experiments were performed for miR-150 and miR-
4772-5p-iso and results for both sepsis and control groups from
Sweden were not statistically difference to the equivalent UK
groups (Figure 3 F&G). When the LDA score was constructed
using the same algorithm, the diagnostic power increased to an
AUC of 0.85 while miR-150 alone had an AUC of 0.80 and miR-
4772-5p-iso had 0.62 (Figure 3 H–J). 81.8% (18/22) sepsis cases
were successfully predicted using LDA score with only a 7.1% (1/
14) false positive rate. LDA scores from the two cohorts generated
an overall diagnostic accuracy of 86%.
Differential expression of microRNAs is maximal in the
monocyte fraction from peripheral blood
To study which cell subset was more likely to contribute to the up-
regulation of miR-4772-5p-iso in sepsis patients, peripheral blood
mononuclear cells (PBMC) from healthy controls, sepsis patients
and SIRS patients were isolated and further purified into CD14+
monocytes and CD14 depleted PBMCs (.90% CD3+ T cells).
Small RNA sequencing of these two fractions revealed that,
although miR-4772-5p-iso is expressed at high abundance in
CD14 depleted PBMCs (Figure 4 A), expression in CD14+
monocytes generated more than a 4 fold change between sepsis
and SIRS patient groups whereas only less than 2 fold change was
observed in CD14 depleted population (Figure 4 B). These data
suggest that the differential microRNA signal came mainly from the
circulating monocyte population.
Toll-like receptor (TLR) ligand stimulation up-regulates
miR-4772-5p-iso expression in primary human
monocytes
As sepsis is driven by microbial signals via TLRs, we sought to
address the mechanistic hypothesis that TLR ligation would cause
the observed microRNA expression changes. Purified primary
human monocytes from healthy volunteers were stimulated by a
broad panel of TLR ligands and the expression of miR-4772-5p-
iso was measured after 8 and 24 hours of stimulation. The
experiment was repeated twice and for each experiments qRT-
PCR was done in triplicates. Data were then normalised to the
percentage of maximum effect of each experiment. There were no
significant changes in expression after 8 hours of culture (data not
shown), but after 24 hours there were significantly increase in the
expression of miR-4772-5p-iso (Figure 4 C) to the majority of TLR
ligands compared to baseline. Primary human monocytes do not
survive well for longer than 24 hours in vitro following TLR ligands
challenge at given does, so later time points were not tested.
Discussion
This study aimed to identify novel biomarkers to rapidly
diagnose sepsis in ICU. Through small RNA sequencing of whole
blood samples, novel and known microRNAs were identified that
were differentially expressed in septic patients and controls. This
finding was further confirmed by qRT-PCR and a composite
signature of miR-150 and miR-4772-5p-iso was generated by an
LDA model which possesses 90.5% specificity and 81.8%
sensitivity in distinguishing sepsis from SIRS. This novel signature
was then validated in an independent cohort and the results in the
two cohorts showed an 86% diagnostic accuracy for sepsis. In vitro
work revealed that miR-4772-5p-iso was upregulated in primary
peripheral blood monocytes after a 24 h challenge with specific
TLR ligands, providing a potential mechanistic explanation for
the observed data.
Research focusing on more accurate and rapid diagnosis of
sepsis has highlighted methods that include specific serum and cell
surface proteins and bacterial DNA detection [25,26]. Neutrophil
CD64 expression was first reported to be increased from patients
with acute bacterial infection compared with healthy controls over
20 years ago [27]. A recent meta-analysis of 14 publications
summarized that the average sensitivity and specificity of
neutrophil CD64 was 79% and 91% respectively [28], which
was reproduced in our study setting. We also found neutrophil
CD64 expression correlated with the APACHE II score, with
indicates the severity of sepsis (Figure S1 in File S1). However, due
to the complexity of using FACS analysis at the patients’ bedside,
CD64 has not been adopted into routine clinical practice.
A large body of research has shown that microRNAs control
important processes such as cell proliferation, adhesion, apoptosis
and angiogenesis (reviewed in [29,30,31]). Recent publications
also demonstrate that microRNAs can be considered as diagnostic
markers [8,9,10,32,33,34]. The recent development of small RNA
deep sequencing has revolutionised microRNA identification,
especially those with potential diagnostic or prognostic value
[35,36,37,38,39].
It has been suggested that decreased plasma miR-150 is a
diagnostic and prognostic marker for sepsis [10]. It was also
reported that serum miR-146a and miR-223 levels were lower in
septic patients compared with SIRS, generating an AUC of 0.858
and 0.804 respectively [14]. Wang et al studied a cohort of 214
sepsis patients and found that a combination of 4 microRNA
Figure 3. Construction and Validation of a Linear Discriminant Model for diagnosing sepsis from SIRS. (A) LDA score was achieved
using linear discriminant analysis (LDA) based on results of miR-4772-5p-iso and miR-150 in UK cohort; Mann-Whitney U test were applied.
*** significant at p,0.001; (B) Prediction plot based on LDA score (X axis) and re probability of sepsis (Y axis), Red dots: Sepsis, Black dots: SIRS; ROC
Curves demonstrate the diagnostic capacities of (C) miR-150 alone, (D) miR-4772-5p-iso alone and (E) LDA score; (F) miR-150 expression and (G) miR-
4772-5p-iso expression of 2 patient groups from both UK and Sweden, Kruskal-Wallis ANOVA test was applied; ROC curves show the diagnostic
power of (H) miR-150 and (I) miR-4772-5p-iso alone; (J) LDA score from Swedish cohort.
doi:10.1371/journal.pone.0075918.g003
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markers in serum (miR-15a, miR-16, miR-193* and miR-483-5p)
and sepsis clinical scores predicted 28 days survival rate with a
sensitivity of 88.5% and a specificity of 90.4% [33]. We employ
massively parallel high throughput small RNA sequencing
technique to identify candidates from the entire microRNAome
that are differentially expressed in whole blood from patients with
sepsis and SIRS. This putative ‘‘sepsis signature’’ was then
validated using real time PCR in a clinical study. Our findings
Figure 4. Expression of miR-4772-5p-iso in CD14+ monocytes between sepsis and SIRS compared with CD14 depleted PBMCs, and
expression levels in healthy monocytes stimulated by TLR ligands. (A) Small RNA sequencing of CD14+monocytes vs CD14 depleted PBMCs
for miR-4772-5p-iso expression in Healthy, Sepsis, and SIRS samples (experiments were performed using RNA from a pool of samples in each group,
see Table S1.). (B) Fold changes of sequencing results based on the number of reads/million in Sepsis vs SIRS group; (C) qRT-PCR results of
microRNA miR-4772-5p-iso expression in CD14+ monocytes from healthy donors stimulated with different TLR ligands for 24 hours; does and source
of TLR ligands listed in methods section. qRT-PCR was done using triplicates. Fold changes were calculated based on RPMI medium alone (see
method) then normalised to percentage of maximum effect in each experiment, error bars represents Standard Error of the Mean (SEM); n = 2.
doi:10.1371/journal.pone.0075918.g004
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confirm that miR-150 is down regulated during sepsis compared
with SIRS and healthy subjects and yielded a comparable AUC of
0.83 [10]. miR-146a and miR-223 were also detected in our
sequencing assays, but did not generate a significant fold change
compared to the other candidates (Figure S2 in File S1). Of
note,our experiments were done using RNAs extracted from
whole blood samples, which contain intracellular microRNAs that
might have contributed to the difference compared to other
published studies. However by using whole blood we were able to
perform deep sequencing, which allowed a novel microRNA to be
discovered. We discarded microRNAs largely contributed by red
cells or platelets (e.g miR-451). We decided to use whole blood
because current extraction methods for serum tend to bias
microRNA expression [40].
Two novel microRNAs, namely miR-342-3p and miR-3173-5p
were also decreased significantly in septic patients compared to
SIRS. Interestingly, the microRNA miR-4772 family was found to
be the only one significantly up-regulated in the sepsis group
compared to healthy subjects. Particular attention was paid to
miR-4772-5p iso, which was significantly upregulated compared
with both healthy subjects and SIRS patients.
Using Linear Discriminant Analysis, choosing a pool of SIRS and
healthy subjects as a control, we successfully constructed a statistical
model using real-time PCR data obtained from a UK training
cohort, which demonstrated miR-150 and miR-4772-5p-iso to be
the best two candidates to diagnose sepsis. This result was cross-
validated with samples from an independent cohort in Sweden of
patients with severe sepsis or septic shock. Patients in the validation
cohort were selected retrospectively from a total of 1093 patients
based on detailed clinical information, lab results and clinical
outcome [19]. Compared to the ICU environment, our second
cohort gave a clearer defined diagnosis which provided more
confidence in evaluating the accuracy of our proposed biomarkers.
Our unpublished data from more than 300 sequencing
experiments in different tissues, such as embryonic cells and
various tumors, show that miR-4772-5p-iso is mainly expressed in
monocytes and T cells, indicating the specificity of this microRNA
for the immune system. This is the only candidate among over 400
microRNAs from the sequencing data that is upregulated.
miR-4772-5p-iso has no murine homologue and it is plausible
that species-specific microRNAs are likely to represent more
specific biomarkers for human disease. These data indicate that
miR-4772-5p-iso may also play an important biological function
during sepsis. miR-4772-5p-iso is located in an intronic region of
IL-18RAP (Figure 2), which was also increased during sepsis. IL-
18 itself has previously been reported to be upregulated during
sepsis [10,41] and given its genomic location adjacent to
IL18RAP, is likely to be co-ordinately regulated.
To determine which blood cell subpopulation was responsible
for the observed microRNA expression changes, we purified
CD14+ monocytes and monocyte-depleted peripheral blood
mononuclear cells (PBMC) from healthy donors. Sequencing data
suggested that although CD14 depleted cells (which are mainly T
lymphocytes) expressed high levels of miR-4772-5p-iso, CD14+
monocytes generated a much better discriminative signal between
sepsis and SIRS. This finding indicated that miR-4772-5p-iso may
be functionally more related to innate rather than adaptive
immunity especially in a situation such as sepsis. Incubate of
monocytes with TLR ligands showed that the majority of TLR
ligands upregulated this particular microRNA. Given that sepsis is
associated with TLR ligation by exogenous microbial ligands,
these data support the hypothesis that upregulation of this specific
microRNA may be a useful mechanistic biomarker and a sensitive
way of detecting TLR ligation in circulating blood monocytes.
In summary, we have identified a microRNA based molecular
signature that reliably discriminates sepsis from SIRS. Given that
this test can be performed rapidly at the point of care, it has the
potential to transform the management of this severe human
disease. Despite the limited sample size in the current study, we
have been able to replicate that initial finding in a separate cohort.
Given the complex nature of sepsis/SIRS, randomised prospective
large scale clinical trials are now needed to determine the value of
this potential microRNA based biomarker in larger patient groups.
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Neutrophil CD64 expression in different groups. (A) Each point
represents the expression of CD64 on neutrophils for an individual
patient expressed as MFI (Mean Fluorescent Intensity). The bar
represents the geometric mean of each group. Kruskal-Wallis
ANOVA test was applied. *** significant at p,0.001. (B) A
representative FACS dot plot showing neutrophils gated by
CD66b and high side scatter. (C)&(D) show histogram of isotype
FITC expression and CD64 expression of two ICU patients
representing high (black line) or low (grey solid) expression of
CD64. (E) ROC Curves demonstrate the diagnostic utility of
CD64 in comparison with WBC, CRP and temperature for sepsis
in ICU. (F) The correlations of neutrophil CD64 with APACHE II
score; (G): The correlations of neutrophil CD64 with SOFA score.
Figure S2. miR-146a and miR-223 expression level in different
groups (UK cohort). Each bar represents the expression of miR-
146a (left) or miR-223 (right) in healthy volunteers, Sepsis patients
or SIRS patients; Kruskal-Wallis ANOVA test was applied. ***
significant at p,0.01; *** significant at p,0.001.
(DOC)
Author Contributions
Conceived and designed the experiments: YM DV KA MHF IZ GL.
Performed the experiments: YM DV SR IZ BT PM. Analyzed the data:
YM DV OD IZ. Contributed reagents/materials/analysis tools: JE MO
BM DHP PO RB. Wrote the paper: YM IZ GL. Acquired Ethic Approval:
YM MHF JE GL.
References
1. Angus DC, Linde-Zwirble WT, Lidicker J, Clermont G, Carcillo J, et al. (2001)
Epidemiology of severe sepsis in the United States: analysis of incidence,
outcome, and associated costs of care. Crit Care Med 29: 1303–1310.
2. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, et al. (2004)
Surviving Sepsis Campaign guidelines for management of severe sepsis and
septic shock. Crit Care Med 32: 858–873.
3. Gaieski DF, Pines JM, Band RA, Mikkelsen ME, Massone R, et al. (2009)
Impact of time to antibiotics on survival in patients with severe sepsis or septic
shock in whom early goal-directed therapy was initiated in the emergency
department. Crit Care Med.
4. Levy MM, Dellinger RP, Townsend SR, Linde-Zwirble WT, Marshall JC, et al.
(2010) The Surviving Sepsis Campaign: results of an international guideline-
based performance improvement program targeting severe sepsis. Intensive Care
Med 36: 222–231.
5. Beale R, Reinhart K, Brunkhorst FM, Dobb G, Levy M, et al. (2009) Promoting
Global Research Excellence in Severe Sepsis (PROGRESS): lessons from an
international sepsis registry. Infection 37: 222–232.
6. Baltimore D, Boldin MP, O’Connell RM, Rao DS, Taganov KD (2008)
MicroRNAs: new regulators of immune cell development and function. Nat
Immunol 9: 839–845.
7. O’Connell RM, Chaudhuri AA, Rao DS, Gibson WS, Balazs AB, et al. (2010)
MicroRNAs enriched in hematopoietic stem cells differentially regulate long-
term hematopoietic output. Proc Natl Acad Sci U S A 107: 14235–14240.
A Validated microRNA Signature for Sepsis
PLOS ONE | www.plosone.org 11 October 2013 | Volume 8 | Issue 10 | e75918
8. Calin GA, Croce CM (2006) MicroRNA signatures in human cancers. Nat Rev
Cancer 6: 857–866.
9. Ji J, Shi J, Budhu A, Yu Z, Forgues M, et al. (2009) MicroRNA expression,
survival, and response to interferon in liver cancer. N Engl J Med 361: 1437–
1447.
10. Vasilescu C, Rossi S, Shimizu M, Tudor S, Veronese A, et al. (2009) MicroRNA
fingerprints identify miR-150 as a plasma prognostic marker in patients with
sepsis. PLoS One 4: e7405.
11. Marcucci G, Radmacher MD, Maharry K, Mrozek K, Ruppert AS, et al. (2008)
MicroRNA expression in cytogenetically normal acute myeloid leukemia.
N Engl J Med 358: 1919–1928.
12. O’Connell RM, Taganov KD, Boldin MP, Cheng G, Baltimore D (2007)
MicroRNA-155 is induced during the macrophage inflammatory response. Proc
Natl Acad Sci U S A 104: 1604–1609.
13. Tili E, Michaille JJ, Cimino A, Costinean S, Dumitru CD, et al. (2007)
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/
TNF-alpha stimulation and their possible roles in regulating the response to
endotoxin shock. J Immunol 179: 5082–5089.
14. Wang JF, Yu ML, Yu G, Bian JJ, Deng XM, et al. (2010) Serum miR-146a and
miR-223 as potential new biomarkers for sepsis. Biochem Biophys Res Commun
394: 184–188.
15. Delfour O VD, Atzorn V, Michot B (2007) The passionate race for microARN
detection and function deciphering.’’ Clarke, N.J and Sanseau, P(eds):
‘‘microARN: Biology, Function and Expression. DNA Press Chapter 5: 38.
16. Dyson A, Singer M (2009) Animal models of sepsis: why does preclinical efficacy
fail to translate to the clinical setting? Crit Care Med 37: S30–37.
17. Deitch EA (2005) Rodent models of intra-abdominal infection. Shock 24 Suppl
1: 19–23.
18. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, et al. (2003) 2001
SCCM/ESICM/ACCP/ATS/SIS International Sepsis Definitions Conference.
Crit Care Med 31: 1250–1256.
19. Josefson P, Stralin K, Ohlin A, Ennefors T, Dragsten B, et al. (2011) Evaluation
of a commercial multiplex PCR test (SeptiFast) in the etiological diagnosis of
community-onset bloodstream infections. Eur J Clin Microbiol Infect Dis 30:
1127–1134.
20. Invitrogen Website, TRIzol Reagent and TRIzol LS Reagent (2011) Available:
http://tools.invitrogen.com/Content/SFS/ProductNotes/F_071215_
Trizol%20and%20Trizol%20LS.pdf. Accessed 2013 Aug 27.
21. Morin RD, O’Connor MD, Griffith M, Kuchenbauer F, Delaney A, et al. (2008)
Application of massively parallel sequencing to microRNA profiling and
discovery in human embryonic stem cells. Genome Res 18: 610–621.
22. Meyer SU, Pfaffl MW, Ulbrich SE (2010) Normalization strategies for
microRNA profiling experiments: a ‘normal’ way to a hidden layer of
complexity? Biotechnol Lett 32: 1777–1788.
23. Jenner RG, Townsend MJ, Jackson I, Sun K, Bouwman RD, et al. (2009) The
transcription factors T-bet and GATA-3 control alternative pathways of T-cell
differentiation through a shared set of target genes. Proc Natl Acad Sci U S A
106: 17876–17881.
24. Taganov KD, Boldin MP, Chang KJ, Baltimore D (2006) NF-kappaB-
dependent induction of microRNA miR-146, an inhibitor targeted to signaling
proteins of innate immune responses. Proc Natl Acad Sci U S A 103: 12481–
12486.
25. Carrigan SD, Scott G, Tabrizian M (2004) Toward resolving the challenges of
sepsis diagnosis. Clin Chem 50: 1301–1314.
26. Ivady B, Beres BJ, Szabo D (2011) Recent advances in sepsis research: novel
biomarkers and therapeutic targets. Curr Med Chem 18: 3211–3225.
27. Simms HH, Frank MM, Quinn TC, Holland S, Gaither TA (1989) Studies on
phagocytosis in patients with acute bacterial infections. J Clin Invest 83: 252–
260.
28. Cid J, Aguinaco R, Sanchez R, Garcia-Pardo G, Llorente A (2010) Neutrophil
CD64 expression as marker of bacterial infection: a systematic review and meta-
analysis. J Infect 60: 313–319.
29. Ruan K, Fang X, Ouyang G (2009) MicroRNAs: novel regulators in the
hallmarks of human cancer. Cancer Lett 285: 116–126.
30. Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 116: 281–297.
31. Bartel DP (2009) MicroRNAs: target recognition and regulatory functions. Cell
136: 215–233.
32. Wang QZ, Xu W, Habib N, Xu R (2009) Potential uses of microRNA in lung
cancer diagnosis, prognosis, and therapy. Curr Cancer Drug Targets 9: 572–
594.
33. Wang H, Zhang P, Chen W, Feng D, Jia Y, et al. (2012) Serum microRNA
signatures identified by Solexa sequencing predict sepsis patients’ mortality: a
prospective observational study. PLoS One 7: e38885.
34. Sun X, Icli B, Wara AK, Belkin N, He S, et al. (2012) MicroRNA-181b regulates
NF-kappaB-mediated vascular inflammation. J Clin Invest 122: 1973–1990.
35. Vaz C, Ahmad HM, Sharma P, Gupta R, Kumar L, et al. (2010) Analysis of
microRNA transcriptome by deep sequencing of small RNA libraries of
peripheral blood. BMC Genomics 11: 288.
36. Schotte D, Moqadam FA, Lange-Turenhout EA, Chen C, van Ijcken WF, et al.
(2011) Discovery of new microRNAs by small RNAome deep sequencing in
childhood acute lymphoblastic leukemia. Leukemia 25: 1389–1399.
37. Ugras S, Brill E, Jacobsen A, Hafner M, Socci ND, et al. (2011) Small RNA
sequencing and functional characterization reveals MicroRNA-143 tumor
suppressor activity in liposarcoma. Cancer Res 71: 5659–5669.
38. Han Y, Chen J, Zhao X, Liang C, Wang Y, et al. (2011) MicroRNA expression
signatures of bladder cancer revealed by deep sequencing. PLoS One 6: e18286.
39. Jima DD, Zhang J, Jacobs C, Richards KL, Dunphy CH, et al. (2010) Deep
sequencing of the small RNA transcriptome of normal and malignant human B
cells identifies hundreds of novel microRNAs. Blood 116: e118–127.
40. Pritchard CC, Kroh E, Wood B, Arroyo JD, Dougherty KJ, et al. (2012) Blood
cell origin of circulating microRNAs: a cautionary note for cancer biomarker
studies. Cancer Prev Res (Phila) 5: 492–497.
41. Standage SW, Wong HR (2011) Biomarkers for pediatric sepsis and septic shock.
Expert Rev Anti Infect Ther 9: 71–79.
A Validated microRNA Signature for Sepsis
PLOS ONE | www.plosone.org 12 October 2013 | Volume 8 | Issue 10 | e75918
